Status:
TERMINATED
A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma
Lead Sponsor:
Washington University School of Medicine
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To determine the overall response rate (CR+PR) of patients with relapsed or refractory multiple myeloma treated with clofarabine.
Detailed Description
To determine the time to response, duration of response, and time to progression of patients treated with clofarabine. To determine the safety and tolerability of clofarabine in these patients.
Eligibility Criteria
Inclusion
- Multiple myeloma diagnosed by standard criteria.
- Measurable levels of monoclonal protein in serum (\>= 0.5 g/dL) or urine (\>= 0.2 g/24 hr).
- At least 1 prior therapies for multiple myeloma with documented evidence of progression on the most recent treatment.
- Age 18 years or older.
- ECOG performance status \<= 2.
- Acceptable organ and marrow function as defined below:
- Hemoglobin \>= 8 gm/dL
- Absolute neutrophil count \>= 1,000/mm3
- Platelets \>= 50,000/mm3
- Total bilirubin \<= 2.5 X institutional upper limit of normal
- AST, ALT \<= 2.5 X institutional upper limit of normal
- Creatinine 1.5 x institutional upper limit of normal
- Normal cardiac function as determined by standard institutional methods
- Women of child bearing potential must agree to use adequate contraception prior to study entry and for the duration of study.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion
- Receiving any other investigational agents.
- Receiving concurrent steroids with a dose equivalent of prednisone of \>= 150 mg/month.
- Pregnant or nursing.
- Active systemic infection considered opportunistic, life threatening or clinically significant at the time of treatment.
- Severe concurrent disease, including severe insulin-dependent diabetes, uncontrolled hypertension, transient ischemic attacks, uncontrolled symptomatic coronary artery disease, or symptomatic CNS involvement or psychiatric illness/social situations that would limit compliance with study requirements.
- History of other malignancy except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast unless the subject has been off treatment and free from disease for \>= 3 years.
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00241371
Start Date
March 1 2005
End Date
December 1 2007
Last Update
August 13 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110